Fennec Pharmaceuticals: CFO Robert Andrade received 3,846 shares

What happened
Robert Andrade, CFO, received 3,846 shares at $5.53 per share on Oct 12, 2026, for $21,268. The filing reports the acquisition as an award/grant or other acquisition.

Key details

• Transaction date and price: Oct 12, 2026 — 3,846 shares at $5.53 per share (total $21,268).
• Shares owned after the transaction: not reported in the filing.
• Footnotes: F1 — shares acquired pursuant to the Fennec Pharmaceuticals Inc. employee stock purchase plan (ESPP) for the Apr 9, 2026 through Oct 12, 2026 purchase period. F2 — shares purchased based on 85% of the closing price of the issuer's common stock on the Nasdaq Capital Market on Apr 9, 2026.
• Filing date: Oct 13, 2026. The filing does not indicate it was late.

Why it may matter
The filing shows an acquisition through the company's ESPP rather than an open-market purchase. This filing does not show why the insider traded or why the company acted.